Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Publication of AR027526A1publicationCriticalpatent/AR027526A1/en
Una formulacion para prevenir la concepcion masculina que comprende una progestina que posee propiedades tanto androgénicas como estrogénicas essorprendentemente eficaz para suprimir la espermatogénesis en varones. Se emplean las progestina Noretiste rona (NET), particularmente sus derivados acetato deNoretisterona y enantato de Noretisterona en dosis suficientes como para inducir la oligozoospermia o la azoospermia en machos. Las formulaciones quecomprenden además un androgeno, tal como un deriv ado de testosterona tal como un éster de testosterona, particularmente undecanoato de testosterona, sonespecialmente eficaces como formulaciones anticonceptivas masculinas.A formulation to prevent the male conception comprising a progestin that possesses both androgenic and estrogenic properties is surprisingly effective in suppressing spermatogenesis in men. The progestin Noretiste rona (NET), particularly its derivatives Noretisterone acetate and Noretisterone enanthate are used in sufficient doses to induce oligozoospermia or azoospermia in males. Formulations that further comprise an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective as male contraceptive formulations.
ARP010100654A2000-02-152001-02-14
MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE
AR027526A1
(en)
A COMPOSITION OF CONTROLLED GALANTAMINE RELEASE, A PROCESS FOR THE PREPARATION OF THE SAME, AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT
15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
ANTI-CONCEPTIVE KIT THAT INCLUDES MEANS FOR THE DAILY ADMINISTRATION OF AN ANTI-CONCEPTIVE AGENT, USE OF A STEROID COMPOUND THAT HAS A DEACTIVITY PROFILE THAT INHERENTLY COMBINES THE PROGESTAGENIC AND STROGENIC ACTIVITIES AND AN ANTI-PROCEPTIVE METHOD
17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.